RenovoRx has added medical-technology executive Richard Stark to its board, expanding the board from six members to seven. The appointment took effect November 18 and gives the company an additional independent director with experience in medical devices, commercialization and strategic transactions.
Stark’s consulting relationship with RenovoRx ended shortly before he joined the board. His new director compensation includes an annual cash retainer and stock options, replacing an arrangement under which he received options but no cash for advisory work.
Key details
- Board appointment: Stark was appointed to a newly created seat and was deemed independent under Nasdaq standards.
- Industry experience: He has more than 30 years in medical technology. He is chief executive of Innoblative Designs, founder and managing member of the medical-technology investment group MedTech Angels, and principal of RAS Consulting Firm. Earlier roles include leading Sanarus Technologies and serving as a senior executive at AngioDynamics. He also serves on the boards of two medical-device companies.
- Consulting arrangement ended: Stark had advised RenovoRx as a strategic commercial consultant since December 2024. That agreement ended November 15. He had received only stock options, not cash, for the consulting work; 12,000 unvested options were forfeited when the arrangement ended.
- Initial director award: On November 18, Stark received options to buy 128,824 shares, with an aggregate grant-date fair value of $120,000. The exercise price is $1.12 per share, the stock’s closing price on the grant date, and the options expire after 10 years.
- Vesting and change of control: The initial award vests in equal monthly installments over 36 months, subject to continued board service. It will vest in full upon a change in control if he remains in service through that event.
- Ongoing compensation: Stark will receive a $40,000 annual cash retainer, paid quarterly, plus any additional fees for committee service. He is also scheduled to receive a prorated option award on October 1, 2027, with a $70,000 aggregate grant-date fair value before proration; that award will vest monthly over 12 months. He will be eligible for the same compensation as RenovoRx’s other nonemployee directors thereafter and can be reimbursed for reasonable board-related travel expenses.
The change adds an independent seat to RenovoRx’s board. Stark’s compensation also shifts from an equity-only consulting arrangement to the company’s outside-director pay structure, which combines cash fees with equity awards.
